Patients with head and neck squamous cell carcinomas (HNSCC) with high cyclin D1 tumor expressions were less likely to respond to neo-adjuvant cisplatin-based CHT and survive, than patients with low expressions of the marker (58 vs. 85%; p < 0.001). This evidence concerns the gene CCND1 and head and neck squamous cell carcinoma.